COVID-19 Vaccine Safety Studies among Vulnerable Populations: A Systematic Review and Meta-

analysis of 120 Observational Studies and Randomized Clinical Trials

Sima Mohammadi¹, Malede Mequanent Sisay¹, Putri Widi Saraswati¹, Alhadi Khogali Osman¹, Nicolaas.P.A Zuithoff¹, Daniel Weibel¹, Miriam Sturkenboom¹, Fariba Ahmadizar^{1,2}

¹Department of Data Science and Biostatistics, Real World Evidence, University Medical Center Utrecht, 3584 CX, Utrecht, The Netherlands

²Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.

Abstract word: 296

Main text word: 3850

Corresponding Author: Fariba Ahmadizar

Email: f.ahmadizar@umcutrecht.nl

Conflicts of interest: All authors declare no conflicts of interest.

Abstract

BACKGROUND

The COVID-19 vaccines were rapidly developed and tested, but concerns about vaccine-related adverse events remain, especially in vulnerable groups like pregnant women, children, and those with certain health conditions. This review aims to summarize rates of such adverse events in individuals often not included in randomized clinical trials (RCT).

METHOD

From December 2019 to February 2022, we searched Embase and Medline for observational studies and RCTs on adverse events post-COVID-19 vaccination in vulnerable groups. We examined serious and non-serious events in individuals with specific medical conditions, infants, children, pregnant individuals, and socioeconomically disadvantaged individuals. Cumulative risks for all events were calculated. The Incidence rate (IR) and 95% confidence intervals were reported for those studies that met the follow-up period criteria based on the referenced literature. For events with data on exposed and unexposed groups, we calculated the odds ratio. Pooled incidence rates were calculated per 1000 person-days using a random-effects model. Sub-group analyses were conducted based on vaccine types and doses, with heterogeneity assessed using I².

FINDINGS

Of the 4,254 papers, 235 met eligibility criteria, including 120 studies with 171,073 participants (113 observational, eight RCTs. We examined 17 severe and 7 non-severe adverse event categories. Lymphadenopathy (IR: 1.95[1.20;3.19]), autoimmune disease and multiple sclerosis flare-up (1.13 [0.47;2.68]), and cardiac symptoms (0.26[0.00;10.58]) were the most severe events. Allergic reactions were more common among autoimmune (7.03[4.10;12.06]) and cancer (4.87[2.21;10.76]) groups. vaccinees who received the second dose of vaccine had higher proportions of disease flare-ups (39.27 [18.08;85.31] vs 22.13 [10.22; 47.93]); cardiac symptoms (6.11[2.05-18.22] vs 3.78[2.53-5.65]); and cardiac events (5.34[1.69;16.90] vs 5.05[1.40,18.19]) in observational studies.

INTERPRETATION

This review highlights COVID-19 vaccine safety in vulnerable populations, enhancing vaccination strategies. Further real-world research is needed to validate and extend our findings, especially in addressing safety gaps among vulnerable groups.

Keywords: Vulnerable population, Special populations, incidence, risk, COVID-19 vaccination, safety, adverse events

Funding

There was no funding source for this study.

Introduction

The rapid development and global deployment of COVID-19 vaccines have been pivotal in the ongoing battle against the pandemic. At the start of the vaccination rollout, the WHO prioritizes the vaccination of populations at high risk of severe COVID-19 to ensure the protection of vulnerable individuals, such as pregnant and lactating women, children, those with underlying health conditions like immunocompromised and autoimmune diseases, who are more likely to experience severe complications from COVID-19¹. While pivotal clinical trials and randomized clinical trials (RCTs) provided crucial safety data for vaccine authorization, including these vulnerable groups was limited, necessitating further investigation into the safety profiles of COVID-19 vaccines within these populations^{2.3}.

This review addresses this gap by comprehensively analysing adverse events of special interest (AESIs) following COVID-19 vaccination, focusing specifically on vulnerable populations. We determined the incidence rate (IR) and prevalence of COVID-19 vaccine-related AESIs within the overall vulnerable population. Additionally, we conducted subgroup analyses for specific groups, such as individuals with particular medical conditions, infants, children, and pregnant individuals, and performed analyses based on vaccine type and dose. These efforts aim to inform vaccination strategies and enhance safety monitoring.

Method

Search strategy and selection criteria

This study is a systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews (PRISMA) requirements. A comprehensive compilation of keywords utilized in each database (Tables S1-2). Embase and Medline databases were established for our study from 14th December 2019 until 21st February 2022. To minimize the possibility of missing relevant literature, all titles and abstracts underwent rigorous independent reviews by three reviewers (A.K.O, P.W.S, M.M.S) using the Rayyan software⁴. Disagreement between reviewers was resolved through the review process involving the fourth and fifth researchers (S.M, F.A).

We included all observational studies (cohort, cross-sectional, and case-control studies) and pivotal clinical trials/RCTs in Phase III/IV, as of December 14th, 2021, that reported AESIs or reactogenicity associated with COVID-19 vaccinations within a specified time window after vaccination. We included all severe and non-severe adverse events associated with the COVID-19 vaccine. Severe adverse events entail those causing considerable harm, requiring medical attention or hospitalization, including systemic allergic reactions, cardiac or neurological symptoms, respiratory symptoms, lymphadenopathy, maternal or neonatal events, and death. Non-severe adverse events include mild effects that do not harm significantly, such as arthralgia, myalgia, fever, fatigue, and gastrointestinal symptoms. We excluded all studies that did not report rates of adverse events, non-English papers, literature, editorial publications, systematic reviews, animal studies, clinical trials in phase I or II, and heterologous vaccine studies.

Our study's inclusion criteria for the target population encompassed immunocompromised individuals (people with HIV, solid organ transplant recipients, hematopoietic cell transplant recipients, and individuals receiving immunosuppressive therapies), cancer (individuals with any malignancy), pregnant and breastfeeding, children under 12 years old and adolescents aged 12-17 years, individuals living with disabilities (such as Down syndrome), migrants (including refugees, internally displaced persons, asylum seekers, undocumented migrants and transgenders).

Data extraction

Four researchers (S.M, M.M.S, P.W.S, A.K.O) retrieved data, assessed the studies' quality, and verified them. An independent investigator confirmed the accuracy of the extracted data (S.M.). We extracted numerical data and information on the subgroups. Study features included study design, sample size, number of vaccinated, number of events in vaccinated, population type, and characteristics (sex, age, country), vaccine platform, dose and brand, adverse event, and follow-up period (days). Vaccines' outcomes were classified according to their organ/system involvement. We selected 24 main outcomes for reporting based on the clinical impact

of the outcomes and available studies. We grouped various terms, synonyms, and closely related outcomes under broader specific categories (Table S3). When multiple outcomes from the same class were presented, we included all of them.

Quality assessment

The New Castle Ottawa checklist and ROBIN-I tool were utilized to evaluate the risk of bias for observational and trials, respectively^{5,6}. Two reviewers (M.M.S, P.W.S) did the risk of bias assessment, verified by a third reviewer (S.M).

Data analysis

We used descriptive statistics to characterize and summarize the included studies. To mitigate the impact of varying follow-up durations across the studies and maintain consistency in follow-up duration for accurate comparison and pooling of data, we assessed each study's follow-up period against predefined criteria derived from referenced guidelines and literature⁷⁻¹⁷ (Table S4). Studies meeting the follow-up period criteria based on referenced literature were included in calculating incidence rates. We calculated cumulative risks (incidence proportion) for all events. For events with available data on exposed and unexposed groups, we calculated the odds ratio (OR) with a 95% CI.

Pooled IRs and 95% CI were calculated on the scale of 1000 person days, and risk was calculated per 1000 observations. We employed the inverse variance method to weigh the effect sizes of the studies based on their respective variances. We used a Random-Effects Model because all studies included in our analysis did not represent a homogeneous population. This model accounts for variations between studies that arise from factors beyond simple sampling error, allowing us to incorporate and address the diversity in study designs, populations, and settings. We used the I² statistic to assess heterogeneity among studies, with values indicating no (0%), low (25%), moderate (50%), or high (75% or more) heterogeneity. Rates or risks without an associated I² value indicate no meta-analysis was conducted for these outcomes. Instead, these values represent descriptive findings from individual studies. We explored asymmetry and P value to assess the publication bias using a funnel plot and an Egger's test. We initially performed analysis to estimate the cumulative risk in the overall vulnerable population for each adverse event and subsequently conducted subgroup analyses based on vaccine dose, vaccine type, and specific study populations. Pooled effects were reported for outcomes with data from at least two studies or individual studies where data could be pooled meta-analytically. We conducted all meta-analyses using the "Meta" package in R Studio 3.6.0 software.

Results

Following the PRISMA guidelines, we initially retrieved 4,763 articles. After deduplication, 4,254 unique articles underwent screening, 3,957 were excluded based on title and abstract, and 62 were not retrievable due to the unavailability of full-text access. Among the 235 full-text screened studies, 11 were excluded due to mismatch with the target population, three had incorrect exposure, 14 had incorrect outcome, 27 had wrong study design, 28 had wrong publication type, 14 had incomplete data, and two were non-English languages. A total of 136 studies remained eligible for inclusion in the review (Figure 1). Among these, 120 studies^{3,18-135} were included in the meta-analysis. Table S5 provides further details on the descriptive characteristics of the studies included in the analysis.

These studies included populations from over 33 countries/regions (Figure S1). The predominant study design (67.8 %) was cohort studies, followed by (25%) cross-sectional studies, (6.6%) RCTs, and (1.6%) case-control studies.

Using the Newcastle Ottawa scale, among observational studies, 112(28.8%) received a good quality assessment score, while 36% were rated as fair quality and 35.2 as poor quality. Using the ROBIN-I tool, 66.7 of RCTs were rated as having a low risk of bias, 8.3% had some concerns and 25% had a high risk of bias.

Among observational studies, 55.8% reported data for dose 1, 27.5% on dose 2, and 2.5% on doses 3, while 28.3% were unspecified for the vaccine dose. Most studies (64.1%) provided data on mRNA vaccines, while only 10.8% focused on inactivated vaccines and 5% on viral vector vaccines. The remaining studies did not specify the data by vaccine type. A total of 24.1% of studies included populations with auto-immune disease, 24.1% cancer patients, 20% immunocompromised, 13.3% pregnant, 7.5% children and adolescents, 5% multiple sclerosis (MS), 4.1% lactating and 1.6% Down and Dravet syndrome (Table S6).

Allergic reaction

In both cohorts and cross-sectional studies, most allergic reactions occurred among individuals with autoimmune diseases with a pooled proportion of (cohort:7.03[4.10;12.06], $I^2=0.00^{68,77,123}$; cross-sectional: 9.93[4.77;18.19]⁴⁷) followed by cancer individuals (cohort: 2.68,[1.01;10.00], $I^2=0.00^{109,112}$; cross-sectional: 2.91[0.48;17.67], $I^2=0.00)^{32}$. The cohort study revealed that patients with cancer exhibited a higher pooled proportion of allergic reactions after the second vaccine dose (4.87[2.21; 10.76], $I^2=0.00)^{67,104,109,112}$ compared to the first dose (2.68[1.01;10.00], $I^2=0.00)^{109,112}$. Additionally, individuals with autoimmune diseases demonstrated a higher pooled proportion of allergic reactions of allergic reactions after the first dose compared to the second dose respectively, in both cohorts (7.03[4.10;12.06], $I^2=0.00^{68,77,123}$ vs 5.53[3.60;8.48], $I^2=0.00^{66,68,77,118,123}$) and the individual cross-sectional studies (9.93[4.77;18.19] vs 8.94 [4.09;16.90])^{47} (Figure 2 and Table S7).

Accelerated allergic reactions

Three studies assessed accelerated allergic reactions. The data analysis from a study on autoimmune patients, unspecified for dose, showed an incidence rate of 1.82[0.81-2.83], $I^2=0.00^{49}$. According to an individual cross-sectional study on MS patients³¹ and one on lactating women⁴⁶, the IR of allergic reaction within 48 hours is higher in MS than in lactating women (27.81[15.62;40.00] vs 1.28[0.00;16.39]). Accelerated allergic reaction IR is higher in dose 1 than dose 2 in an individual cross-sectional study of 720 MS patients. (27.81[15.62;40.00] vs 13.91[5.29;22.53]) ³¹. There were no significant differences in the pooled IR between vaccination types (mRNA:1.59[0.00;10.21], I²=0.00 vs viral vector: 1.66 [0.00;19.72], I²=0.00)⁴⁹ (Figure 3).

Cardiac event

A prospective, multicenter RCT revealed that the IR of myocardial infarction is $0.13 (0.03; 0.53)^{21}$. The IR of cardiac events in a big population-based cohort of 2,494,282 children and adolescents vaccinated with mRNA is higher after the second dose (0.01[0.01; 0.01], vs first dose 0.0024[0.0004; 0.0043])⁶¹ (Table S7). The pooled IR of two cohorts on autoimmune patients represent the IR of 0.02[0.00; 4.14], I²=0.95 for myocarditis and pericarditis^{80,97}, and the pooled IR in cross-sectional studies on autoimmune patients revealed that mRNA vaccines had greater IR of the cardiac

event than viral vector; (viral vector dose 1: 0.00[0.00;0.00], $I^2=0.00\%$ vs mRNA dose 1: 1.19[0.00;0.56], $I^2=0.00\%$; viral vector dose 2: 0.00[0.00;80.42], $I^2=0.00$ vs. mRNA dose 2: 0.36[0.00;0.78], $I^2=0.00)^{38}$ (Figure 4)

Cardiac symptoms

Similar to cardiac events, the cardiac symptoms such as chest pain and palpitation, have a higher pooled IR following dose 2 $(0.75[0.00;5175.62], I^2=0.00)^{85,121}$ compared to dose 1 $(0.26[0.00;10.58], I^2=43\%)^{68,85,121}$ in the overall pooled analysis of cohort studies. Similarly, a cross-sectional study on children vaccinated with an mRNA vaccine supports this finding, reporting higher cardiac symptom rates after dose 2 (277.11 [170.58; 283.64]) compared to dose 1 $(184.56 [135.78; 233.34])^{26}$ (Figure 5).

Disease Deterioration/Flare/Recurrence

In cohort studies, the pooled IR of disease deterioration/flare /recurrence in the MS population is 0.79[0.00;2.40], I²=0.00 for vaccine dose 1⁵⁵. The pooled IRs comparing doses 1 and 2 revealed that other autoimmune diseases experience more flares than the MS Population. (dose1: 0.92[0.00;2.01], I²=33%; vs 0.79[0.00;2.40], I²=0.00)^{68,77,123} and; (dose2: 2.73[0.56;4.89], I²=97% vs 1.42 [0.00;12.55], I²=90%)^{68,77,118,123}. Based on the findings of cohort studies, there is a higher pooled IR of disease recurrence/flare/deterioration after receiving the second dose (2.40[0.81;3.99], I2=96%)^{55,68,77,118,123} of the mRNA vaccine than after the first dose; (0.85[0.36;1.34], I²=18%)^{55,68,77,123}. However, the pooled effect from the analysis of autoimmune patients vaccinated with mRNA vaccine in cross-sectional studies showed the opposite trend (dose 1: 4.02[0.00;8.92], I²=0.00; vs dose 2: 1.61[0.42;2.80])³⁹ (Figure 6).

Respiratory symptoms

The analysis of two RCTs on autoimmune vaccinated with inactivated vaccine following dose 1 represented the pooled IR of 2.15 [0.01;4.29], I²=56% for respiratory symptoms^{22,23}. Pooled IR of respiratory symptoms in the overall vulnerable population is higher in dose 2 compared to the dose , in both cohorts (1.73[0.28;10.41], $I^2=0.00^{85,119}$ vs 0.06[0.00;0.19], $I^2=0.00^{68,85,119}$) and cross-sectional (5.83[0.21;158.58], $I^2=94\%$ vs 4.13[0.02;712.07], $I^2=94\%$)^{26,38} studies. The analysis of cross-sectional studies exhibits a greater IR of respiratory symptoms in mRNA vaccinated compared to the viral vector vaccinated; (mRNA, dose1: 60.58[0.00;320.09], $I^2=96\%^{26,38}$, vs viral vector

dose1: 1.20[0.00;14.60)], I²=0.00³⁸); (mRNA, dose2: 74.52[0.00; 394.91], I²=97%^{26,38}, vs viral vector dose2: 0.00 [0.00; 4.29])³⁸ (Figure 7).

Hospitalization

Two separate cohort studies, one involving 90 individuals with autoimmune diseases⁷⁷ and another encompassing approximately 444,000 children and adolescents⁸⁰, found that the proportion of hospitalization is notably higher among autoimmune patients in comparison to adolescents who have received mRNA vaccines. (dose1: 22.22[2.70;77.98] vs 0.08[0.06;0.11]); (dose2: 11.11[0.28;60.36] vs 0.16[0.13;0.20]). In both cohort and cross-sectional studies, adolescents who received the mRNA vaccine experienced double the number of reported hospitalizations after the second dose compared to the first dose (cohort dose1: 0.08[0.05;0.11] vs dose 2: 0.16[0.13-0.20])⁸⁰; (cross-sectional dose1: 53.69[31.00,85.73], dose 2: 120.88[84.69;165.55])²⁶, (Figure 8 and Table S7).

Lymphadenopathy

The pooled IR of lymphadenopathy following dose 2 is higher than the first dose in the cohort, cross-sectional, and case-control studies (cohort of cancer patients: 1.80[0.00;3.67], $I^2=0.00^{93,116}$; vs 0.77[0.00;1.66], $I^2=0.00^{93,110,116}$); (cross-sectional of autoimmune patients: 0.57[0.00;1.43], $I^2=0.00$ vs 0.15[0.00;0.54], $I^2=0.00^{38}$; individual case-control of pregnant women: 2.93[0.90;4.96] vs 0.37[0.00;1.08])¹³⁴ (Figure 9 and Table S7).

Hypertensive disorder

There was no difference in the pooled proportion of hypertensive disorder observed across different doses in immunocompromised patients in cohort studies (dose 1: $16.39[0.41;87.99]^{92}$ vs dose 2: 18.71[8.84;39.59], $I^2=0.00^{67,92}$ vs dose 3: $16.39[0.04;116.38])^{92}$. The pooled proportion of hypertensive disorder among organ transplant recipients after the second dose was higher compared to that among individuals with autoimmune diseases (18.71[8.84;39.59], $I^2=0.00^{67,92}$; vs $3.31[0.40;11.89]^{118}$). An individual cohort study on transplant recipient reported no cases of hypertension after receiving the inactivated vaccine⁶⁷. All studies reporting this outcome were conducted among mRNA-vaccinated individuals^{67,92,118} (Figure 10).

Neurological symptoms

Analysis of cohort and case-control studies separately indicates that the pooled proportion of neurological symptoms including Paresthesia, numbness, facial tingling, tremor, and tinnitus per 1000 observations in overall vulnerable population is higher after the second dose compared to the first dose (cohort: 16.43[2.32;116.19], $I^2=15\%^{55,67}$; vs 10.83[0.00;1000.00], $I^2=63\%^{55,121}$); (case-control: 27.69[0.03;1000.00], $I^2=87\%$ vs 24.59[13.45;44.95], $I^2=0.00$)^{133,134}; however, the pooled effect in cross-sectional studies and RCTs showed the opposite pattern (cross-sectional dose 1: 17.69[1.68;185.93], $I^2=45\%$, vs dose2: 8.23[0.96;70.59], $I^2=0.00$)³⁸; (trial dose1: 47.63[0.00;1000.00], $I^2=67\%$ vs dose 2: 36.89[0.00;1000.00], $I^2=32\%$)^{22,23} (Figure 11). Subgroup analyses by population or vaccine type did not reveal any clear trends in proportions.

Neurological event

Analysis of cohort studies in cancer patients showed no significant difference between the pooled proportion of neurological events in doses 1 and 2 (dose1: 5.05[1.40;18.19], I²=0.00 vs dose2: 5.34[1.69;16.90], I²=0.00)¹¹² (Figure 12).

Maternal and neonatal outcome

The most prevalent maternal outcomes following COVID-19 vaccination were gestational hypertension by the pooled proportion of 36.57[0.00;1000.00], $I^2=88\%^{115}$ per 1000 observations followed by spontaneous or induced abortion (8.55[3.59;20.37], $I^2=96\%$)¹²⁶ and stillbirth (3.65[2.64;5.05], $I^2=0.00$)^{115,123}. The most common neonatal outcomes were small for gestational age by a proportion of 73.18[9.67;553.68], $I^2=95\%^{106,120,123}$, followed by neonatal hospitalization (33.89[4.10;280.14], $I^2=43\%$)^{106,115,123} (Figure 13-14-15).

Gestational hypertension

Cohort studies investigating maternal hypertensive disorders after mRNA vaccination indicate a higher pooled proportion of hypertensive disorders after the second dose (50.13[35.71;68.1]) compared to the first dose (14.28[0.00;1000.00], $I^2=99\%^{70,120}$) (Figure 13).

Abortion

In cohort studies of pregnant women vaccinated with mRNA vaccines, the pooled IR of spontaneous or induced abortion is 0.17[0.06;0.5], $I^2=95\%^{126}$ (Figure 14).

Small for gestational age (SGA)

The odd ratio (OR) of SGA infants born from mothers vaccinated with the first dose of COVID-19 mRNA vaccines in the two respective cohorts were $0.66[0.4;1.07]^{120}$ and $0.97[0.87;1.08]^{71}$, and the OR of SGA following dose 2 in one of these cohorts was $1.21[0.56;2.64]^{120}$ (Figure 15).

Stillbirth

No stillbirth cases were reported in the two cohorts of 140 pregnant women who received either the mRNA or viral vector vaccine¹¹⁵. Among 7,530 cases in a separate cohort⁷⁰ and 827 cases in a cross-sectional study⁵¹ receiving mRNA vaccine during pregnancy, only one stillbirth case was reported (Table S7).

Thromboembolism

An RCT of 544 cancer patients vaccinated with mRNA vaccines presented that the proportion of thromboembolism events was 9.19[3.83-22.08] per 1000 observations²¹. A cohort study of 140 pregnant women showed no case of events in this population¹¹⁵. A cross-sectional study of over 2500 inflammatory bowel syndrome patients showed that the proportion of thromboembolic events was higher following dose two compared to dose one (1.16[0.37;3.58] vs 0.77[0.19;3.08])³⁵ (Table S7).

Deaths

Two cohort studies involving pregnant women who received mRNA/viral vector vaccines found no reported deaths^{70,115}. In another cohort of 435 MS patients who received the second dose of the mRNA vaccine, one death was reported⁵⁵. Additionally, in a trial of 1,902 cancer patients who received the mRNA vaccine, one death was reported²⁴. In a study of over 16,600 newborns born from mothers who received the COVID-19 vaccine, the OR of neonatal deaths was 0.84[0.43;1.72], suggesting no significant differences between neonatal death in vaccinated and unvaccinated mothers⁷¹ (Supplementary Table 7).

Non-sever outcomes

Within the scope of our analysis, fatigue, myalgia, arthralgia, and gastrointestinal symptoms were the most prevalent symptoms. Figures 16 to 22 encapsulate the data about non-severe systemic outcomes and their sub-grouped analysis (Table S8).

Publication Bias

The funnel plots represent each reported effect estimate as an individual point. Each study includes several rates for different outcomes and vaccines, consequently, each study contributes multiple points to the plot. The funnel plots exhibit some skewness, suggesting potential publication bias within this literature, however, due to the generally low standard errors, the likelihood of publication bias attributed to sample size appears to be minimal (Figure S2-3).

Discussion

The rapid development and widespread deployment of COVID-19 vaccines have been pivotal in mitigating the impact of the global pandemic. However, given the limited representation of vulnerable groups in pivotal clinical trials and RCTs, further investigation into vaccine safety within these populations is imperative to inform vaccination strategies and enhance safety monitoring efforts. This study pooled the IRs and proportions of COVID-19 vaccine-induced outcomes across diverse vaccine platforms, study designs, and populations. Our finding showed that among the reported outcomes, the top four most prevalent severe events were lymphadenopathy, autoimmune disease and MS flare-up, and cardiac symptoms. Allergic reactions were more common among patients with autoimmune diseases, followed by cancer patients, who most often experienced lymphadenopathy. Autoimmune disease patients had more flare-ups than those with MS. Lymphadenopathy, cardiac events, cardiac symptoms, and hospitalizations were more frequent after the second vaccine dose. Cardiac events and hypertensive disorders were more common with mRNA vaccines, while allergic reactions were more frequent with viral vector vaccines. The adverse effects of mRNA vaccines are higher due to their earlier approval and broader distribution¹⁶. No link was found between COVID-19 vaccination and maternal or neonatal outcomes. Cardiac events were more common with mRNA vaccines in cohort studies, especially after the second dose. However, cross-sectional studies had conflicting results due to smaller sample sizes and vaccine brand variability.

The literature reviews on the cancer population revealed a significant number of cases of lymphadenopathy following COVID-19 vaccination, advising clinicians to rely on the patient's clinical context and current resources to avoid probable disease progression and therapy changes^{136 137}. Negahdaripour et al.'s study supports overall vaccine safety for cancer patients ¹³⁸, supporting our finding that serious adverse events are rare. Our results aligned with this study, showing nuanced susceptibility in immunocompromised individuals. This susceptibility might depend on the medication type administered to the patients, which impacts the activation of immune cells and their seropositivity¹³⁸. Studies recommend avoiding vaccination during immunosuppressive treatment or waiting 4-6 months post-medication to minimize complications and ensure safety¹³⁸.

Our findings revealed a high IR of flare-ups in autoimmune diseases, particularly after the second vaccine dose. This is different from Patrick's study, where autoimmune-immunocompromised individuals did not experience an exacerbation, possibly due to ongoing immunosuppressive treatment¹³⁹. Shabani et al.'s systematic review shows more flare-ups in immune-mediated diseases compared to MS, and higher flare-ups with mRNA vaccines than with viral vector and inactivated vaccines¹⁴⁰, aligning with our research findings. It suggests avoiding vaccination during disease flare-ups and tapering steroid therapy¹⁴¹. Yang's study demonstrated disease flares after inactivated COVID-19 vaccination¹⁴¹. Our study compared flare-ups across different vaccine types, finding higher rates with mRNA vaccines and fewer on other vaccine types, though further investigation is needed¹⁴². In our study, cardiac events were rare in immunocompromised, autoimmune, and cancer patients, aligning with a systematic review that found myocarditis and pericarditis rates post-vaccination similar to the general population¹⁴³. Thus, emphasizing the significance of the overall advantages of COVID-19 vaccination.

Our analysis showed that severe events in vaccinated children and adolescents are rare, consistent with systematic reviews confirming the rarity of serious adverse events^{139,141}. Hause et al. noted a few serious adverse events in children under five, including anaphylaxis and afebrile seizures, with the majority being non-serious events like fever, rash, vomiting, urticaria, and fatigue¹⁴⁴.

Annamaria et al.'s review identifies common pregnancy-related AESIs^{141,145}. Our findings aligned, showing SGA as the most prevalent fetal adverse event and pregnancy loss as the most common maternal outcome. Unlike the Annamaria study, we found a neonatal death rate of 1.44 per 1000 person days, but no significant link to vaccination

(OR: 0.8). Both Kang's and Li Yang's studies found no significant difference in adverse event rates post-COVID-19 vaccination between HIV patients and healthy controls^{146,147}. Although our study, which included HIV patients in the immunocompromised group, found a high rate of non-severe adverse events, these rates may not differ from those in healthy populations, indicating the need for further investigation.

To our knowledge, this study is the first comprehensive systematic review that addresses a crucial gap in understanding the safety profiles of COVID-19 vaccines, particularly within vulnerable populations. Our study encompassed a diverse range of vulnerable populations, including immunocompromised individuals, cancer patients, pregnant and breastfeeding women, children, adolescents, individuals with disabilities, and migrants. We analysed observational studies and clinical trial data to elucidate these groups' IRs of adverse events following COVID-19 vaccination. Broad inclusion criteria and detailed subgroup analyses of vaccine types and doses provided valuable insights for vaccination strategies and safety monitoring.

Our study has several limitations that should be acknowledged. We reduced heterogeneity in the overall analysis through subgroup analyses. However, the optimal approach would have been to group individuals with varying immune characteristics, such as those with HIV or drug-induced immunosuppression into a single category. However, separate analyses for these subgroups were not feasible due to the limited number of available studies. This limitation highlights the need for more granular data in future research to allow for more precise subgroup analyses. Limited gender information restricted sex-based analyses, and certain populations, such as refugees and prisoners, were not presented in any study. Furthermore, some studies utilize passive surveillance methods, such as self-reported data, which may not be as reliable as data reported by the healthcare system following direct observation. In addition the predominance of studies from high-income countries limits generalizability to low- and middle-income settings. Finally, small sample sizes, wide confidence intervals, and varying study quality highlight the need for larger and more representative datasets in future research.

Conclusion

In conclusion, our review provides valuable insights into the safety profiles of COVID-19 vaccines within vulnerable populations. By systematically analyzing various adverse events across diverse populations and vaccine platforms,

our findings contribute to the ongoing efforts to optimize vaccination strategies and enhance safety monitoring efforts in the fight against the COVID-19 pandemic. Further research using real-world data is warranted to validate and expand upon our findings, focusing on addressing gaps in vaccine safety knowledge within vulnerable populations.

References

1. World Health O. WHO SAGE roadmap for prioritizing uses of COVID-19 vaccines in the context of limited supply: an approach to inform planning and subsequent recommendations based on epidemiological setting and vaccine supply scenarios, first issued 20 October 2020, latest update 16 July 2021. CC BY-NC-SA 3.0 IGO. Geneva: World Health Organization, 2021.

2. Mehrabi Nejad M-M, Moosaie F, Dehghanbanadaki H, et al. Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis. *European journal of medical research* 2022; **27**(1): 23.

3. Blakeway H, Prasad S, Kalafat E, et al. COVID-19 vaccination during pregnancy: coverage and safety. *American journal of obstetrics and gynecology* 2022; **226**(2): 236. e1-. e14.

4. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan—a web and mobile app for systematic reviews. *Systematic reviews* 2016; **5**: 1-10.

5. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2000.

6. Eldridge S, Campbell M, Campbell M, et al. Revised Cochrane risk of bias tool for randomized trials (RoB 2.0): additional considerations for cluster-randomized trials. *Cochrane Methods Cochrane Database Syst Rev* 2016; **10**.

7. Yoshikawa T, Miki S, Nakao T, Koshino S, Hayashi N, Abe O. Axillary lymphadenopathy after Pfizer-BioNTech and Moderna COVID-19 vaccination: MRI evaluation. *Radiology* 2023; **306**(1): 270-8.

8. Mahdiabadi S, Rezaei N. Anaphylaxis and allergic reactions to COVID-19 vaccines: A narrative review of characteristics and potential obstacles on achieving herd immunity. *Health Science Reports* 2022; **5**(5): e787.

9. Husby A, Hansen JV, Fosbøl E, et al. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study. *bmj* 2021; **375**.

10. Patone M, Mei XW, Handunnetthi L, et al. Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection. *Nature medicine* 2022; **28**(2): 410-22.

11. Pawlowski C, Rincón-Hekking J, Awasthi S, et al. Cerebral Venous Sinus Thrombosis is not Significantly Linked to COVID-19 Vaccines or Non-COVID Vaccines in a Large Multi-State Health System. *J* Stroke Cerebrovasc Dis 2021; **30**(10): 105923.

12. Dawoud R, Haddad D, Shah V, et al. COVID-19 Vaccine-Related Arthritis: A Descriptive Study of Case Reports on a Rare Complication. *Cureus* 2022; **14**(7): e26702.

13. Kadali RAK, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. *Int J Infect Dis* 2021; **106**: 376-81.

14. Frontera JA, Tamborska AA, Doheim MF, et al. Neurological Events Reported after COVID-19 Vaccines: An Analysis of VAERS. *Ann Neurol* 2022; **91**(6): 756-71.

15. Hyun H, Song JY, Seong H, et al. Polyarthralgia and Myalgia Syndrome after ChAdOx1 nCOV-19 Vaccination. *J Korean Med Sci* 2021; **36**(34): e245.

16. SeyedAlinaghi S, Karimi A, Pashaei Z, et al. Safety and Adverse Events Related to COVID-19 mRNA Vaccines; a Systematic Review. *Arch Acad Emerg Med* 2022; **10**(1): e41.

17. Hunt RH, East JE, Lanas A, et al. COVID-19 and Gastrointestinal Disease: Implications for the Gastroenterologist. *Dig Dis* 2021; **39**(2): 119-39.

18. Ali K, Berman G, Zhou H, et al. Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents. *N Engl J Med* 2021; **385**(24): 2241-51.

19. Frater J, Ewer KJ, Ogbe A, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. *Lancet HIV* 2021; **8**(8): e474-e85.

20. Frenck RW, Jr., Klein NP, Kitchin N, et al. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. *N Engl J Med* 2021; **385**(3): 239-50.

21. Oosting SF, van der Veldt AAM, GeurtsvanKessel CH, et al. mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. *Lancet Oncol* 2021; **22**(12): 1681-91.

22. Sampaio-Barros PD, Medeiros-Ribeiro AC, Luppino-Assad AP, et al. SARS-CoV-2 vaccine in patients with systemic sclerosis: impact of disease subtype and therapy. *Rheumatology (Oxford)* 2022; **61**(Si2): Si169-si74.

23. Shinjo SK, de Souza FHC, Borges IBP, et al. Systemic autoimmune myopathies: a prospective phase 4 controlled trial of an inactivated virus vaccine against SARS-CoV-2. *Rheumatology (Oxford)* 2022; **61**(8): 3351-61.

24. Thomas SJ, Perez JL, Lockhart SP, et al. Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trial. *Vaccine* 2022; **40**(10): 1483-92.

25. Walter EB, Talaat KR, Sabharwal C, et al. Evaluation of the BNT162b2 Covid-19 Vaccine in Children 5 to 11 Years of Age. *N Engl J Med* 2022; **386**(1): 35-46.

26. Alamer E, Alhazmi A, Qasir NA, et al. Side Effects of COVID-19 Pfizer-BioNTech mRNA Vaccine in Children Aged 12-18 Years in Saudi Arabia. *Vaccines (Basel)* 2021; **9**(11).

27. Ali H, Ngo D, Aribi A, et al. Safety and Tolerability of SARS-CoV2 Emergency-Use Authorized Vaccines for Allogeneic Hematopoietic Stem Cell Transplant Recipients. *Transplant Cell Ther* 2021; **27**(11): 938.e1-.e6.

28. Alonso R, Chertcoff A, Leguizamón FDV, et al. Evaluation of short-term safety of COVID-19 vaccines in patients with multiple sclerosis from Latin America. *Mult Scler J Exp Transl Clin* 2021; **7**(4): 20552173211061543.

29. Bartels LE, Ammitzbøll C, Andersen JB, et al. Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis. *Rheumatol Int* 2021; **41**(11): 1925-31.

30. Botwin GJ, Li D, Figueiredo J, et al. Adverse Events After SARS-CoV-2 mRNA Vaccination Among Patients With Inflammatory Bowel Disease. *Am J Gastroenterol* 2021; **116**(8): 1746-51.

31. Briggs FBS, Mateen FJ, Schmidt H, et al. COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis. *Neurol Neuroimmunol Neuroinflamm* 2022; **9**(1).

32. Matovina Brko G, Popovic M, Jovic M, et al. COVID-19 vaccines and cancer patients: acceptance, attitudes and safety. *J buon* 2021; **26**(5): 2183-90.

33. Cherian S, Paul A, Ahmed S, et al. Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey. *Rheumatol Int* 2021; **41**(8): 1441-5.

34. Clayton LM, Balestrini S, Cross JH, et al. The impact of SARS-CoV-2 vaccination in Dravet syndrome: A UK survey. *Epilepsy Behav* 2021; **124**: 108258.

35. Ellul P, Revés J, Abreu B, et al. Implementation and Short-term Adverse Events of Anti-SARS-CoV-2 Vaccines in Inflammatory Bowel Disease Patients: An International Web-based Survey. *J Crohns Colitis* 2022; **16**(7): 1070-8.

36. Esquivel-Valerio JA, Skinner-Taylor CM, Moreno-Arquieta IA, et al. Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study. *Rheumatol Int* 2021; **41**(12): 2105-8.

37. Forster M, Wuerstlein R, Koenig A, et al. COVID-19 vaccination in patients with breast cancer and gynecological malignancies: A German perspective. *Breast* 2021; **60**: 214-22.

38. Fragoulis GE, Bournia VK, Mavrea E, et al. COVID-19 vaccine safety and nocebo-prone associated hesitancy in patients with systemic rheumatic diseases: a cross-sectional study. *Rheumatol Int* 2022; **42**(1): 31-9.

39. Haslak F, Gunalp A, Cebi MN, et al. Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: A single-center study. *Int J Rheum Dis* 2022; **25**(3): 353-63.

40. Allen-Philbey K, Stennett A, Begum T, et al. Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis. *Mult Scler Relat Disord* 2021; **52**: 103028.

41. Kadali RAK, Janagama R, Peruru SR, et al. Adverse effects of COVID-19 messenger RNA vaccines among pregnant women: a cross-sectional study on healthcare workers with detailed self-reported symptoms. *Am J Obstet Gynecol* 2021; **225**(4): 458-60.

42. Lechosa-Muñiz C, Paz-Zulueta M, Mendez-Legaza JM, et al. Induction of SARS-CoV-2-Specific IgG and IgA in Serum and Milk with Different SARS-CoV-2 Vaccines in Breastfeeding Women: A Cross-Sectional Study in Northern Spain. *Int J Environ Res Public Health* 2021; **18**(16).

43. Liu Y, Han J, Li X, et al. COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity. *Vaccines (Basel)* 2021; **9**(12).

44. Lotan I, Romanow G, Levy M. Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases. *Mult Scler Relat Disord* 2021; **55**: 103189.

45. Lotan I, Wilf-Yarkoni A, Friedman Y, Stiebel-Kalish H, Steiner I, Hellmann MA. Safety of the BNT162b2 COVID-19 vaccine in multiple sclerosis (MS): Early experience from a tertiary MS center in Israel. *Eur J Neurol* 2021; **28**(11): 3742-8.

46. McLaurin-Jiang S, Garner CD, Krutsch K, Hale TW. Maternal and Child Symptoms Following COVID-19 Vaccination Among Breastfeeding Mothers. *Breastfeed Med* 2021; **16**(9): 702-9.

47. Orfanoudaki E, Zacharopoulou E, Kitsou V, et al. Real-World Use and Adverse Events of SARS-CoV-2 Vaccination in Greek Patients with Inflammatory Bowel Disease. *J Clin Med* 2022; **11**(3).

48. Rotondo C, Cantatore FP, Fornaro M, et al. Preliminary Data on Post Market Safety Profiles of COVID 19 Vaccines in Rheumatic Diseases: Assessments on Various Vaccines in Use, Different Rheumatic Disease Subtypes, and Immunosuppressive Therapies: A Two-Centers Study. *Vaccines (Basel)* 2021; **9**(7).

49. Sattui SE, Liew JW, Kennedy K, et al. Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine Survey. *RMD Open* 2021; **7**(3).

50. Shapiro Ben David S, Shamir-Stein N, Baruch Gez S, Lerner U, Rahamim-Cohen D, Ekka Zohar A. Reactogenicity of a third BNT162b2 mRNA COVID-19 vaccine among immunocompromised individuals and seniors - A nationwide survey. *Clin Immunol* 2021; **232**: 108860.

51. Shimabukuro TT, Kim SY, Myers TR, et al. Preliminary Findings of mRNA Covid-19 Vaccine Safety in Pregnant Persons. *N Engl J Med* 2021; **384**(24): 2273-82.

52. Wang Q, Lv C, Han X, Shen M, Kuang Y. A Web-Based Survey on Factors for Unvaccination and Adverse Reactions of SARS-CoV-2 Vaccines in Chinese Patients with Psoriasis. *J Inflamm Res* 2021; **14**: 6265-73.

53. Zdanowski W, Markiewicz A, Zdanowska N, Lipińska J, Waśniewski T. Tolerability of the BNT162b2 COVID-19 Vaccine during Pregnancy among Polish Healthcare Professionals. *Vaccines (Basel)* 2022; **10**(2).

54. Li M, Yuan J, Lv G, Brown J, Jiang X, Lu ZK. Myocarditis and Pericarditis following COVID-19 Vaccination: Inequalities in Age and Vaccine Types. *J Pers Med* 2021; **11**(11).

55. Achiron A, Dolev M, Menascu S, et al. COVID-19 vaccination in patients with multiple sclerosis: What we have learnt by February 2021. *Mult Scler* 2021; **27**(6): 864-70.

56. Aharon D, Lederman M, Ghofranian A, et al. In Vitro Fertilization and Early Pregnancy Outcomes After Coronavirus Disease 2019 (COVID-19) Vaccination. *Obstet Gynecol* 2022; **139**(4): 490-7.

57. Ariamanesh M, Porouhan P, PeyroShabany B, et al. Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (BBIBP-CorV) in Patients with Malignancy. *Cancer Invest* 2022; **40**(1): 26-34.

58. Avivi I, Balaban R, Shragai T, et al. Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma. *Br J Haematol* 2021; **195**(2): 186-93.

59. Benjamini O, Rokach L, Itchaki G, et al. Safety and efficacy of the BNT162b mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. *Haematologica* 2022; **107**(3): 625-34.

60. Cavanna L, Citterio C, Biasini C, et al. COVID-19 vaccines in adult cancer patients with solid tumours undergoing active treatment: Seropositivity and safety. A prospective observational study in Italy. *Eur J Cancer* 2021; **157**: 441-9.

61. Chua GT, Kwan MYW, Chui CSL, et al. Epidemiology of Acute Myocarditis/Pericarditis in Hong Kong Adolescents Following Comirnaty Vaccination. *Clin Infect Dis* 2022; **75**(4): 673-81.

62. Citu IM, Citu C, Gorun F, et al. Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester. *Viruses* 2022; **14**(2).

63. Collier AY, McMahan K, Yu J, et al. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. *Jama* 2021; **325**(23): 2370-80.

64. Di Noia V, Pimpinelli F, Renna D, et al. Immunogenicity and Safety of COVID-19 Vaccine BNT162b2 for Patients with Solid Cancer: A Large Cohort Prospective Study from a Single Institution. *Clin Cancer Res* 2021; **27**(24): 6815-23.

65. Dreyer-Alster S, Menascu S, Mandel M, et al. COVID-19 vaccination in patients with multiple sclerosis: Safety and humoral efficacy of the third booster dose. *J Neurol Sci* 2022; **434**: 120155.

66. Rabinowitz KM, Navon M, Edelman-Klapper H, et al. Anti-TNFα Treatment Impairs Long-Term Immune Responses to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases. *Vaccines (Basel)* 2022; **10**(8).

67. Erol Ç, Yanık Yalçın T, Sarı N, et al. Differences in Antibody Responses Between an Inactivated SARS-CoV-2 Vaccine and the BNT162b2 mRNA Vaccine in Solid-Organ Transplant Recipients. *Exp Clin Transplant* 2021; **19**(12): 1334-40.

68. Furer V, Eviatar T, Zisman D, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study. *Ann Rheum Dis* 2021; **80**(10): 1330-8.

69. Golan Y, Prahl M, Cassidy AG, et al. COVID-19 mRNA Vaccination in Lactation: Assessment of Adverse Events and Vaccine Related Antibodies in Mother-Infant Dyads. *Front Immunol* 2021; **12**: 777103.

70. Goldshtein I, Nevo D, Steinberg DM, et al. Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women. *Jama* 2021; **326**(8): 728-35.

71. Goldshtein I, Steinberg DM, Kuint J, et al. Association of BNT162b2 COVID-19 Vaccination During Pregnancy With Neonatal and Early Infant Outcomes. *JAMA Pediatr* 2022; **176**(5): 470-7.

72. Goshen-Lago T, Waldhorn I, Holland R, et al. Serologic Status and Toxic Effects of the SARS-CoV-2 BNT162b2 Vaccine in Patients Undergoing Treatment for Cancer. *JAMA Oncol* 2021; **7**(10): 1507-13.

73. Gray KJ, Bordt EA, Atyeo C, et al. Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study. *Am J Obstet Gynecol* 2021; **225**(3): 303.e1-.e17.

74. Greenberg RS, Ruddy JA, Boyarsky BJ, et al. Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with multiple myeloma. *BMC Cancer* 2021; **21**(1): 1354.

75. Hadi YB, Thakkar S, Shah-Khan SM, Hutson W, Sarwari A, Singh S. COVID-19 Vaccination Is Safe and Effective in Patients With Inflammatory Bowel Disease: Analysis of a Large Multi-institutional Research Network in the United States. *Gastroenterology* 2021; **161**(4): 1336-9.e3.

76. Hall VG, Ferreira VH, lerullo M, et al. Humoral and cellular immune response and safety of twodose SARS-CoV-2 mRNA-1273 vaccine in solid organ transplant recipients. *Am J Transplant* 2021; **21**(12): 3980-9.

77. Heshin-Bekenstein M, Ziv A, Toplak N, et al. Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications. *Rheumatology (Oxford)* 2022; **61**(11): 4263-72.

78. Hod T, Ben-David A, Olmer L, et al. Humoral Response of Renal Transplant Recipients to the BNT162b2 SARS-CoV-2 mRNA Vaccine Using Both RBD lgG and Neutralizing Antibodies. *Transplantation* 2021; **105**(11): e234-e43.

Jovicevic V, Ivanovic J, Andabaka M, et al. COVID-19 and vaccination against SARS-CoV-2 in patients with neuromyelitis optica spectrum disorders. *Mult Scler Relat Disord* 2022; 57: 103320.
Lee JS, Choi H, Shin SH, et al. Characterization of Brighton Collaboration criteria for myocarditis

and pericarditis following COVID-19 vaccine in Korean adolescents. *Vaccine* 2024; 42(14): 3333-6.
81. Jyssum I, Kared H, Tran TT, et al. Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. *Lancet Rheumatol* 2022; 4(3): e177-e87.

82. Karacin C, Eren T, Zeynelgil E, et al. Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy. *Future Oncol* 2021; **17**(33): 4447-56.

83. Kian W, Zemel M, Kestenbaum EH, et al. Safety of the BNT162b2 mRNA COVID-19 vaccine in oncologic patients undergoing numerous cancer treatment options: A retrospective single-center study. *Medicine (Baltimore)* 2022; **101**(2): e28561.

84. Lasagna A, Agustoni F, Percivalle E, et al. A snapshot of the immunogenicity, efficacy and safety of a full course of BNT162b2 anti-SARS-CoV-2 vaccine in cancer patients treated with PD-1/PD-L1 inhibitors: a longitudinal cohort study. *ESMO Open* 2021; **6**(5): 100272.

85. Levy I, Wieder-Finesod A, Litchevsky V, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. *Clin Microbiol Infect* 2021; **27**(12): 1851-5.

86. Ligumsky H, Safadi E, Etan T, et al. Immunogenicity and Safety of the BNT162b2 mRNA COVID-19 Vaccine Among Actively Treated Cancer Patients. *J Natl Cancer Inst* 2022; **114**(2): 203-9.

87. Linardou H, Spanakis N, Koliou GA, et al. Responses to SARS-CoV-2 Vaccination in Patients with Cancer (ReCOVer Study): A Prospective Cohort Study of the Hellenic Cooperative Oncology Group. *Cancers (Basel)* 2021; **13**(18).

88. Liontos M, Terpos E, Markellos C, et al. Immunological Response to COVID-19 Vaccination in Ovarian Cancer Patients Receiving PARP Inhibitors. *Vaccines (Basel)* 2021; **9**(10).

89. Low JM, Lee LY, Ng YPM, Zhong Y, Amin Z. Breastfeeding Mother and Child Clinical Outcomes After COVID-19 Vaccination. *J Hum Lact* 2022; **38**(1): 37-42.

90. Ma Y, Liu N, Wang Y, et al. Immune checkpoint blocking impact and nomogram prediction of COVID-19 inactivated vaccine seroconversion in patients with cancer: a propensity-score matched analysis. *J Immunother Cancer* 2021; **9**(11).

91. Machado PM, Lawson-Tovey S, Strangfeld A, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. *Ann Rheum Dis* 2022; **81**(5): 695-709.

92. Massa F, Cremoni M, Gérard A, et al. Safety and cross-variant immunogenicity of a three-dose COVID-19 mRNA vaccine regimen in kidney transplant recipients. *EBioMedicine* 2021; **73**: 103679.

93. Matkowska-Kocjan A, Owoc-Lempach J, Chruszcz J, et al. The COVID-19 mRNA BNT163b2 Vaccine Was Well Tolerated and Highly Immunogenic in Young Adults in Long Follow-Up after Haematopoietic Stem Cell Transplantation. *Vaccines (Basel)* 2021; **9**(10).

94. Medeiros-Ribeiro AC, Aikawa NE, Saad CGS, et al. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. *Nat Med* 2021; **27**(10): 1744-51.

95. Medina-Pestana J, Covas DT, Viana LA, et al. Inactivated Whole-virus Vaccine Triggers Low Response Against SARS-CoV-2 Infection Among Renal Transplant Patients: Prospective Phase 4 Study Results. *Transplantation* 2022; **106**(4): 853-61.

96. Nakahara A, Biggio JR, Elmayan A, Williams FB. Safety-Related Outcomes of Novel mRNA COVID-19 Vaccines in Pregnancy. *Am J Perinatol* 2022; **39**(13): 1484-8.

97. Oster ME, Shay DK, Su JR, et al. Myocarditis Cases Reported After mRNA-Based COVID-19 Vaccination in the US From December 2020 to August 2021. *Jama* 2022; **327**(4): 331-40.

98. Palaia I, Caruso G, Di Donato V, et al. Pfizer-BioNTech COVID-19 Vaccine in Gynecologic Oncology Patients: A Prospective Cohort Study. *Vaccines (Basel)* 2021; **10**(1).

99. Peet CJ, Papadopoulou C, Sombrito BRM, Wood MR, Lachmann HJ. COVID-19 and autoinflammatory diseases: prevalence and outcomes of infection and early experience of vaccination in patients on biologics. *Rheumatol Adv Pract* 2021; **5**(2): rkab043.

100. Peled Y, Ram E, Lavee J, et al. BNT162b2 vaccination in heart transplant recipients: Clinical experience and antibody response. *J Heart Lung Transplant* 2021; **40**(8): 759-62.

101. Pham MN, Murugesan K, Banaei N, et al. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects. *J Allergy Clin Immunol* 2022; **149**(3): 907-11.e3.

102. Pimpinelli F, Marchesi F, Piaggio G, et al. Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution. *J Hematol Oncol* 2021; **14**(1): 81.

103. Pinte L, Negoi F, Ionescu GD, et al. COVID-19 Vaccine Does Not Increase the Risk of Disease Flare-Ups among Patients with Autoimmune and Immune-Mediated Diseases. *J Pers Med* 2021; **11**(12).

104. Rabinowich L, Grupper A, Baruch R, et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. *J Hepatol* 2021; **75**(2): 435-8.

105. Revon-Riviere G, Ninove L, Min V, et al. The BNT162b2 mRNA COVID-19 vaccine in adolescents and young adults with cancer: A monocentric experience. *Eur J Cancer* 2021; **154**: 30-4.

106. Rottenstreich M, Sela HY, Rotem R, Kadish E, Wiener-Well Y, Grisaru-Granovsky S. Covid-19 vaccination during the third trimester of pregnancy: rate of vaccination and maternal and neonatal outcomes, a multicentre retrospective cohort study. *Bjog* 2022; **129**(2): 248-55.

107. Russo G, Lai Q, Poli L, et al. SARS-COV-2 vaccination with BNT162B2 in renal transplant patients: Risk factors for impaired response and immunological implications. *Clin Transplant* 2022; **36**(1): e14495.

108. Sanders JF, Bemelman FJ, Messchendorp AL, et al. The RECOVAC Immune-response Study: The Immunogenicity, Tolerability, and Safety of COVID-19 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With a Kidney Transplant. *Transplantation* 2022; **106**(4): 821-34.

109. Shulman RM, Weinberg DS, Ross EA, et al. Adverse Events Reported by Patients With Cancer After Administration of a 2-Dose mRNA COVID-19 Vaccine. *J Natl Compr Canc Netw* 2022; **20**(2): 160-6.
110. So ACP, McGrath H, Ting J, et al. COVID-19 Vaccine Safety in Cancer Patients: A Single Centre Experience. *Cancers (Basel)* 2021; **13**(14).

111. Spinelli FR, Favalli EG, Garufi C, et al. Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine. *Arthritis Res Ther* 2022; **24**(1): 21.

112. Strobel SB, Machiraju D, Kälber KA, Hassel JC. Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment. *Cancer Immunol Immunother* 2022; **71**(8): 2051-6.

113. Tamura T, Ninomiya K, Kubo T, et al. Short-term safety of an anti-severe acute respiratory syndrome coronavirus 2 messenger RNA vaccine for patients with advanced lung cancer treated with anticancer drugs: A multicenter, prospective, observational study. *Thorac Cancer* 2022; **13**(3): 453-9.

114. Tanner R, Starr N, Chan G, et al. Humoral response to SARS-CoV-2 adenovirus vector vaccination (ChAdOx1 nCoV-19 [AZD1222]) in heart transplant recipients aged 18 to 70 years of age. *J Heart Lung Transplant* 2022; **41**(4): 492-500.

115. Theiler RN, Wick M, Mehta R, Weaver AL, Virk A, Swift M. Pregnancy and birth outcomes after SARS-CoV-2 vaccination in pregnancy. *Am J Obstet Gynecol MFM* 2021; **3**(6): 100467.

116. Trillo Aliaga P, Trapani D, Sandoval JL, et al. Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials. *Cancers (Basel)* 2021; **13**(22).

117. Tsimafeyeu I, Volkova M, Alekseeva G, et al. Safety and preliminary efficacy of the Gam-COVID-Vac vaccine and outcomes of SARS-CoV-2 infection in Russian patients with genitourinary malignancies. *J Hematol Oncol* 2021; **14**(1): 192.

118. Tzioufas AG, Bakasis AD, Goules AV, et al. A prospective multicenter study assessing humoral immunogenicity and safety of the mRNA SARS-CoV-2 vaccines in Greek patients with systemic autoimmune and autoinflammatory rheumatic diseases. *J Autoimmun* 2021; **125**: 102743.

119. Valentini D, Cotugno N, Scoppola V, et al. Safety and Long-Term Immunogenicity of BNT162b2 Vaccine in Individuals with Down Syndrome. *J Clin Med* 2022; **11**(3).

120. Wainstock T, Yoles I, Sergienko R, Sheiner E. Prenatal maternal COVID-19 vaccination and pregnancy outcomes. *Vaccine* 2021; **39**(41): 6037-40.

121. Watcharananan SP, Jaru-Ampornpan P, Sahawongcharoen S, et al. Comparison of the immunogenicity of ChAdOx1 nCoV-19 vaccine against the wild-type and delta variants in kidney transplant recipients and healthy volunteers. *Am J Transplant* 2022; **22**(5): 1459-66.

122. Watanabe M, Yakushijin K, Funakoshi Y, et al. The Safety and Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Japanese Patients after Allogeneic Stem Cell Transplantation. *Vaccines* (*Basel*) 2022; **10**(2).

123. Weaver KN, Zhang X, Dai X, et al. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID. *Inflamm Bowel Dis* 2022; **28**(10): 1497-505.

124. Yasin Al, Aydin SG, Sümbül B, et al. Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study. *Future Oncol* 2022; **18**(10): 1235-44.

125. Zagouri F, Terpos E, Fiste O, et al. SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors. *Breast* 2021; **60**: 58-61.

126. Head Zauche L, Wallace B, Smoots AN, et al. Receipt of mRNA COVID-19 vaccines preconception and during pregnancy and risk of self-reported spontaneous abortions, CDC v-safe COVID-19 Vaccine Pregnancy Registry 2020-21. *Res Sq* 2021.

127. Bernstine H, Priss M, Anati T, et al. Axillary Lymph Nodes Hypermetabolism After BNT162b2 mRNA COVID-19 Vaccination in Cancer Patients Undergoing 18F-FDG PET/CT: A Cohort Study. *Clin Nucl Med* 2021; **46**(5): 396-401.

128. Bleicher I, Kadour-Peero E, Sagi-Dain L, Sagi S. Early exploration of COVID-19 vaccination safety and effectiveness during pregnancy: interim descriptive data from a prospective observational study. *Vaccine* 2021; **39**(44): 6535-8.

129. Mark C, Gupta S, Punnett A, et al. Safety of administration of BNT162b2 mRNA (Pfizer-BioNTech) COVID-19 vaccine in youths and young adults with a history of acute lymphoblastic leukemia and allergy to PEG-asparaginase. *Pediatr Blood Cancer* 2021; **68**(11): e29295.

130. Naranbhai V, Pernat CA, Gavralidis A, et al. Immunogenicity and Reactogenicity of SARS-CoV-2 Vaccines in Patients With Cancer: The CANVAX Cohort Study. *J Clin Oncol* 2022; **40**(1): 12-23.

131. Peled Y, Ram E, Lavee J, et al. Third dose of the BNT162b2 vaccine in heart transplant recipients: Immunogenicity and clinical experience. *J Heart Lung Transplant* 2022; **41**(2): 148-57.

132. Skroza N, Bernardini N, Tolino E, et al. Safety and Impact of Anti-COVID-19 Vaccines in Psoriatic Patients Treated with Biologics: A Real Life Experience. *J Clin Med* 2021; **10**(15).

133. Aikawa NE, Kupa LVK, Pasoto SG, et al. Immunogenicity and safety of two doses of the CoronaVac SARS-CoV-2 vaccine in SARS-CoV-2 seropositive and seronegative patients with autoimmune rheumatic diseases in Brazil: a subgroup analysis of a phase 4 prospective study. *Lancet Rheumatol* 2022; **4**(2): e113-e24.

134. Bookstein Peretz S, Regev N, Novick L, et al. Short-term outcome of pregnant women vaccinated with BNT162b2 mRNA COVID-19 vaccine. *Ultrasound Obstet Gynecol* 2021; **58**(3): 450-6.

135. Bergman P, Blennow O, Hansson L, et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. *EBioMedicine* 2021; **74**: 103705.

136. Garreffa E, Hamad A, O'Sullivan CC, et al. Regional lymphadenopathy following COVID-19 vaccination: Literature review and considerations for patient management in breast cancer care. *Eur J Cancer* 2021; **159**: 38-51.

137. Keshavarz P, Yazdanpanah F, Rafiee F, Mizandari M. Lymphadenopathy Following COVID-19 Vaccination: Imaging Findings Review. *Acad Radiol* 2021; **28**(8): 1058-71.

138. Negahdaripour M, Shafiekhani M, Moezzi SMI, et al. Administration of COVID-19 vaccines in immunocompromised patients. *Int Immunopharmacol* 2021; **99**: 108021.

139. Katoto PD, Kakubu MA, Tamuzi JL, et al. Immunogenicity and reactogenicity of COVID-19 Pfizer-BioNTech (Bnt162b2) mRNA vaccination in immunocompromised adolescents and young adults: a systematic review and meta-analyses. *Expert Rev Vaccines* 2023; **22**(1): 378-92.

140. Shabani M, Shobeiri P, Nouri S, et al. Risk of flare or relapse in patients with immune-mediated diseases following SARS-CoV-2 vaccination: a systematic review and meta-analysis. *Eur J Med Res* 2024; **29**(1): 55.

141. Yan Z, Yang M, Lai CL. COVID-19 Vaccinations: A Comprehensive Review of Their Safety and Efficacy in Special Populations. *Vaccines (Basel)* 2021; **9**(10).

142. Fan Y, Geng Y, Wang Y, et al. Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines. *Ann Rheum Dis* 2022; **81**(3): 443-5.
143. Akhtar Z, Trent M, Moa A, Tan TC, Fröbert O, MacIntyre CR. The impact of COVID-19 and COVID vaccination on cardiovascular outcomes. *Eur Heart J Suppl* 2023; **25**(Suppl A): A42-a9.

144. Hause AM, Marquez P, Zhang B, et al. COVID-19 mRNA Vaccine Safety Among Children Aged 6 Months-5 Years - United States, June 18, 2022-August 21, 2022. *MMWR Morb Mortal Wkly Rep* 2022; **71**(35): 1115-20.

145. Mascolo A, di Mauro G, Fraenza F, et al. Maternal, fetal and neonatal outcomes among pregnant women receiving COVID-19 vaccination: The preg-co-vax study. *Front Immunol* 2022; **13**: 965171.

146. Kang L, Shang W, Gao P, Wang Y, Liu J, Liu M. Immunogenicity and Safety of COVID-19 Vaccines among People Living with HIV: A Systematic Review and Meta-Analysis. *Vaccines (Basel)* 2022; **10**(9).

147. Li HJ, Yang QC, Yao YY, et al. COVID-19 vaccination effectiveness and safety in vulnerable populations: a meta-analysis of 33 observational studies. *Front Pharmacol* 2023; **14**: 1144824.

Figure 1. PRISMA



Figure 2. Allergic Reactio	n Pooled Incidence Proportion
----------------------------	-------------------------------

Study Design	Dose	Population type	Vaccine type	N. studies	N. individuals		IP (95% CI)
Cohort						1	
	1			6*	6157	н	6.08 (4.09 to 9.06)
	2			10*	6337	н	5.61 (4.18 to 7.53)
	1	Lactating		1	31		0.00 (0.00 to 112.19)
	1	Pregnant		1	84		0.00 (0.00 to 42.96)
	2	Lactating		1	31		0.00 (0.00 to 112.19)
	2	Pregnant		1	84	•	11.90 (0.30 to 64.55)
	1	Autoimmune		3*	4092	HH	7.03 (4.10 to 12.06)
	2	Autoimmune		5*	4646	н	5.53 (3.60 to 8.48)
	1	Cancer		2*	1950	•	2.68 (1.01 to 10.00)
	2	Cancer		4*	1576	i ⊷-i	4.87 (2.21 to 10.76)
	1		mRNA	5*	5798	H	5.39 (3.02 to 9.62)
	2		mRNA	9*	6119	н	5.53 (3.93 to 7.77)
	1		Viralvector	1	161	• • • • • • • • • • • • • • • • • • • •	12.42 (1.51 to 44.15)
	2		Inactivated	1	31		0.00 (0.00 to 112.19)
Cross -Sectiona	al						
	1			2*	1609	H A I	8.47 (3.61 to 19.89)
	2			2*	1609	H	7.62 (3.32 to 17.46)
	1		mRNA	1	77		0.00 (0.00 to 46.78)
	1		Inactivated	1	205		0.00 (0.00 to 17.83)
	2		mRNA	1	77		0.00 (0.00 to 46.78)
	2		Inactivated	1	205		0.00 (0.00 to 17.83)
	1	Autoimmune		1	1007	H+++1	9.93 (4.77 to 18.19)
	2	Autoimmune		1	1007	HHHH	8.94 (4.09 to 16.90)
	1	Cancer		1*	602	•	2.91 (0.48 to 17.67)
	2	Cancer		1*	602	•	2.91 (0.48 to 17.67)
						0 10	10
						Incidence Rate	

* The analysis includes collaborative analysis of data within a single study and across multiple studies.

IP: Incidence Proportion

Figure 3. Accelerated Allergic Reaction Pooled Incidence Rate

Study Design	Dose	Population type	Vaccine type	N. studies	N. individuals	5	IR (95% CI)
Cross-section	al						
	1			2*	5174		
	1	Multiple sclerosis		1	719		27.81 (15.62 to 40.00)
	2	Multiple sclerosis		1	720		13.91 (5.29 to 22.53)
	1	Lactating	mRNA	1*	4455	•	1.28 (0.00 to 16.39)
	unspecified	Autoimmune		1*	5689	+	1.82 (0.81 to 2.83)
	unspecified		Viralvector	1*	695	•	1.66 (0.00 to 19.72)
	unspecified		mRNA	1*	2132	•	1.59 (0.00 to 10.21)
						0	100
						Increased Incidence	\rightarrow

* The analysis includes collaborative analysis of data within a single study and across multiple studies

Study Design	Dose	Population type	Vaccine type	N. studies	N. individuals	5		IR (95% CI)
Trial								
	unspecified			1	791	•1		0.13 (0.03 to 0.53)
Cohort ^								
	1	Children and adolescents	mRNA	1	178163			0.00 (0.00 to 0.00)
	2	Children and adolescents	mRNA	1	178163			0.01 (0.01 to 0.01)
Cross-sectional								
	1	Autoimmune	mRNA	1*	394	-	• •	7.23 (0.51 to 102.50)
	1	Autoimmune	Viralvector	1*	44		·→	43.30 (4.21 to 445.75)
	2	Autoimmune		1*	441	Hert		0.39 (0.08 to 0.69)
	2	Autoimmune	mRNA	1*	394			0.36 (0.00 to 0.78)
	2	Autoimmune	Viralvector	1*	44			0.00 (0.00 to 4.29)
							1	0
						<u>ل</u>	Incidence Rate	

Figure 4. Cardiac Event Pooled Incidence Rate

* The analysis includes collaborative analysis of data within a single study and across multiple studies

[^] The numbers in this plot for cohort study are rounded to align with adjacent numbers for consistency.

IR: Incidence Rate

Figure 5. Cardiac Symptoms Pooled Incidence Rate

Study Design	Dose	Population type	Vaccine type	N. studies	N. individuals		IR (95% CI)
Cohort							
	1			3	1085		0.26 (0.01 to 10.58)
	2			2	278		
	1		mRNA	2	950		0.11 (0.00 to 0.48)
	1		Viralvector	1	135		0.00 (0.00 to 7.57)
	1	Immunocompromised		1	143		0.00 (0.00 to 0.94)
	1	Autoimmune		1	807	•	0.10 (0.00 to 0.24)
	1	Cancer		1	135	4	0.00 (0.00 to 0.57)
	2	Immunocompromised	mRNA	1	143	•	0.46 (0.00 to 1.36)
	2	Cancer	Viralvector	1	135	←	0.00 (0.00 to 7.57)
Cross-section	al					Į.	
	1	Children	mRNA	1	298		184.56 (135.78 to 233.34)
	2	Children	mRNA	1	273		227.11 (170.58 to 283.64)
						0	100
						> Incidence rate	\rightarrow

Figure 6. Disease Flare-up Pooled Incidence Rate

Study Design	Dose	Population type	Vaccine type	N. studies	N. individuals		IR (95% CI)
Cohort							
	1			4*	1652		1.13 (0.47 to 2.68)
	1	Autoimmune		3	1097		0.92 (0.00 to 2.01)
	1	Multiple sclerosis		1*	555		0.79 (0.00 to 2.40)
	1		mRNA	3*	1491		0.85 (0.36 to 1.34)
	1		Viralvector	1	161		0.88 (0.00 to 2.62)
	2		mRNA	5*	5201	H	2.40 (0.81 to 3.99)
	2	Multiple sclerosis	mRNA	1*	435		
	2	Autoimmune	mRNA	4*	4766	·	2.73 (0.56 to 4.89)
Cross-section	al						
	1			2*	279	F	4.09 (2.98 to 5.63)
	1	Multiple sclerosis		1	33		
	1	Autoimmune	mRNA	1*	246		4.02 (0.00 to 8.92)
	2	Autoimmune	mRNA	1	247		1.61 (0.42 to 2.80)
						0 Incidence rate	10 →

* The analysis includes collaborative analysis of data within a single study and across multiple studies.

IR: Incidence Rate

0	-						
Study Design	Dose	Population type	Vaccine type	N. studies	N. individuals		IR (95% CI)
Trial						1	
	1	Autoimmune	Inactivated	2*	363	PH .	2.14 (0.01 to 4.29)
Cohort							
	1		mRNA	2*	219	•	1.73 (0.28 to 10.41)
	2		mRNA	3	1026	•	0.06 (0.00 to 0.19)
	1	Down syndrome	mRNA	1*	76	(e 1	3.57 (0.00 to 10.57)
	1	Immunocompromised	mRNA	1	143	+	1.07 (0.00 to 2.28)
	2	Down syndrome	mRNA	1	76	↔	0.00 (0.00 to 6.74)
	2	Immunocompromised	mRNA	1	143		0.00 (0.00 to 0.74)
	2	Autoimmune	mRNA	1	807	•	0.05 (0.00 to 0.15)
Cross-section	al						
	1			2*	1407		5.83 (0.21 to 158.58)
	2			2*	1407		4.13 (0.02 to 712.07)
	1	Children and adolescents		1	965		184.56 (135.78 to 233.34)
	2	Children and adolescents		1	965		227.11 (170.58 to 283.64)
	1	Autoimmune		1*	441	•	0.29 (0.00 to 0.81)
	2	Autoimmune		1*	441	•	0.15 (0.00 to 0.67)
	1		Viralvector	1*	441	•	1.20 (0.00 to 14.60)
	2		Viralvector	1	441	(0.00 (0.00 to 4.29)
	1		mRNA	2*	1407	• • •	60.58 (0.00 to 320.09)

Figure 7. Respiratory Symptoms Pooled Incidence Rate

* The analysis includes collaborative analysis of data within a single study and across multiple studies.

2*

2*

mRNA

1407

ò

Incidence Rate

74.52 (0.00 to 394.91)

100

IR: Incidence Rate

2

Figure 8. Hospitalization Pooled Incidence Proportion



IP: Incidence Proportion

Figure 9. Lymphadenopathy Pooled Incidence Rate

Study Design	Dose	Population type	Vaccine type	N. studies	N. individuals		IR (95% CI)
Cohort							
	1	Cancer		3*	551	H	0.77 (0.00 to 1.66)
	1	Cancer	mRNA	1	65		
	2			3*	424	·	1.95 (1.20 to 3.19)
	2	Cancer		2*	178		1.80 (0.00 to 3.67)
	2	Immunocompromised		1	235		1.67 (0.00 to 3.99)
	2		mRNA	2	300		1.82 (0.00 to 5.74)
Cross-section	al					1	
	1	Autoimmune		1*	441	•	0.15 (0.00 to 0.54)
	2	Autoimmune		1*	441		0.57 (0.00 to 1.34)
	1	Autoimmune	mRNA	1*	394		0.13 (0.00 to 1.74)
	1	Autoimmune	Viralvector	1*	47	-	
	2	Autoimmune	mRNA	1*	394		0.54 (0.00 to 3.38)
	2	Autoimmune	Viralvector	1	44		0.00 (0.00 to 4.29)
						0	10
						Incidence Rate	

* The analysis includes collaborative analysis of data within a single study and across multiple studies.

Study Design	Dose	Population type	Vaccine type	N. studies	N. individuals		IP (95% CI)
Cohort							
	1	Immunocompromised	mRNA	1	61	•	16.39 (0.41 to 87.99)
	2			3*	714	••••••	8.09 (1.59 to 41.14)
	2	Immunocompromised		2*	109		18.71 (8.84 to 39.59)
	2	Autoimmune		1	605	•	3.31 (0.40 to 11.89)
	2		Inactivated	1	31		0.00 (0.00 to 112.19)
	2		mRNA	3	683	$\bullet \longrightarrow$	8.19 (0.49 to 135.66)
	3	Immunocompromised	mRNA	1	61	•	16.39 (0.41 to 87.99)
							0
						Incidence Rate	

Figure 10. Hypertensive Disorder Pooled Incidence Proportion

* The analysis includes collaborative analysis of data within each single study and across multiple studies.

IP: Incidence Proportion

Figure 11. Neurological Symptoms Pooled Incidence Proportion

Study Design	Dose	Population type	Vaccine type	N. studies	N. individuals		IP (95% CI)
Trial						1	
	1	Autoimmune	Inactivated	2*	363	\mapsto	47.63 (0.00 to 1000.00)
	2	Autoimmune	Inactivated	2*	363	\rightarrow	36.89 (0.00 to 1000.00)
Cohort							
	1			2	638	, O , ,	10.83 (0.00 to 1000.00)
	2			2*	483	→ →	16.43 (2.32 to 116.19)
	1	Multiple sclerosis	mRNA		555	• • ••	5.41 (1.12 to 15.71)
	1	Immunocompromised	Viralvector	1	83	• • • • • • • • • • • • • • • • • • • •	24.10 (2.93 to 84.35)
	2	Multiple sclerosis		1	435	⊷ ⊷i	11.49 (3.74 to 26.62)
	2	Immunocompromised		2*	48	— — →	38.51 (0.02 to 1000.00)
	2		mRNA	2	452	\rightarrow	20.71 (0.00 to 1000.00)
	2		Inactivated	1	31	,	0.00 (0.00 to 112.19)
Cross-Sectiona	al						
	1	Autoimmune		1*	441	• • • • • • • • • • • • • • • • • • •	17.69 (1.68 to 185.93)
	2	Autoimmune		1*	438	•	8.23 (0.96 to 70.59)
	1	Autoimmune	mRNA	1*	394		9.20 (0.00 to 1000.00)
	1	Autoimmune	Viralvector	1*	47		42.19 (0.00 to 1000.00)
	2	Autoimmune	mRNA	1*	394	 ,	9.20 (0.00 to 1000.00)
	2	Autoimmune	Viralvector	1	44		0.00 (0.00 to 80.42)
Case-control							
	1			2	25	→ →→→	24.59 (13.45 to 44.95)
	2			2	28	\longmapsto	27.69 (0.03 to 1000.00)
	1	Pregnant	mRNA	1	9		23.08 (10.61 to 43.35)
	1	Autoimmune	Inactivated	1	16	i	25.48 (14.63 to 41.05)
	2	Pregnant	mRNA	1	18	·	46.15 (27.58 to 71.96)
	2	Autoimmune	Inactivated	1	10	→→→→	15.92 (7.66 to 29.09)
						0 10	00
						> Incidence Rate	

* The analysis includes collaborative analysis of data within a single study and across multiple studies.

IP: Incidence Proportion

Figure 12. Neurological Events Pooled Incidence Proportion

Study Design	Dose	Population type	Vaccine type	N. studies	N. individuals		IP (95% CI)
Cohort							
	1	Cancer		1*	198	•	→ 5.05 (1.40 to 18.19)
	2			2*	267	·	5.62 (4.11 to 7.68)
	2	Cancer		1*	187	•	→ 5.34 (1.69 to 16.90)
	2	Immunocompromised	mRNA	1	80		→ 0.00 (0.00 to 45.06)
	unspecified			2*	890	•	→ 2.81 (0.34 to 22.92)
	unspecified	Cancer		1*	89	-	→ 0.00 (0.00 to 40.60)
	unspecified	Pregnant	mRNA	1	712		1.40 (0.04 to 7.80)
						0	10
						Incidence Rate	*

* The analysis includes collaborative analysis of data within a single study and across multiple studies

IP: Incidence Proportion

Figure 13. Gestational Hypertension Pooled Incidence Proportion



* The analysis includes collaborative analysis of data within a single study and across multiple studies.

IP: Incidence Proportion

Figure 14. Spontaneous or Induced Abortion Pooled Incidence Rate

Study Design	Dose	Vaccine type	N. studies	N. individual	S	IR (95% CI)
Cohort						
	1	mRNA	1	15060		1.62 (1.18 to 2.22)
	Any	mRNA	1*	2456	el .	0.17 (0.06 to 0.50)
					0	10
					Incidence Rate	\rightarrow

* The analysis includes collaborative analysis of data within a single study and across multiple studies.

Figure 15. Small for Gestational Age Odd Ratio

Study Design	Dose	Vaccine type	N. studies	N. individuals		OR (95% CI)
Cohort					1	
	1	mRNA	1	4399	H	0.66 (0.40 to 1.07)
	1	mRNA	1	24289		0.97 (0.87 to 1.08)
	2	mRNA	1	4399	H	1.21 (0.56 to 2.64)
	any		3	6706	н	1.02 (0.82 to 1.26)
					0	10
					Incidence Rate	\rightarrow

OR: Odd Ratio

Figure 16. Arthralgia Pooled Incidence Rate

Study Design	Dose	Population type	Vaccine type	N.studies	N.individuals		IR (95% CI)
Trial						1	
	1			4	8358	• • •	5.94 (0.89 to 39.35)
	2			4	8359	•	9.40 (1.27 to 69.48)
	1	Children and adolescents		3	8254		7.54 (0.00 to 28.42)
	1	HIV		1	104		13.22 (1.63 to 20.70)
	2	Children and adolescents		3	8254	· · · · · · · · · · · · · · · · · · ·	16.36 (0.00 to 67.50)
	2	HIV		1	104		13.22 (1.63 to 24.82)
Cohort						1	
	1			13*	4279	H+H	5.19 (3.06 to 8.78)
	2			8*	4873		7.48 (2.84 to 19.68)
	1	Autoimmune		4*	1908		13.00 (0.00 to 26.87)
	1	Lactating		1*	48	н	3.93 (2.87 to 4.99)
	1	Cancer		8*	2715		5.62 (0.00 to 11.69)
	2	Autoimmune		2*	2314	• · · · · ·	2.91 (0.00 to 76.64)
	2	Lactating		1*	48		14.59 (9.85 to 19.33)
	2	Cancer		5*	2446		3.35 (0.37 to 6.34)
	1		mRNA	11*	4453		7.12 (2.47 to 11.76)
	2		mRNA	7*	4397		14.20 (2.16 to 26.25)
Cross-section	al						
	1			4*	20913		7.53 (1.52 to 37.28)
	2			4*	20471		→ 35.81 (10.80 to 118.74)
	1	Pregnant		1*	19252	(•	4.72 (0.00 to 22.91)
	1	Multiple sclerosis		1	719		152.99 (124.40 to 181.58
	1	Cancer		1	218		4.91 (2.42 to 7.40)
	1	Autoimmune	Viralvector	1	724		3.45 (0.00 to 10.76)
	2	Pregnant		1	19252		→ 37.33 (0.00 to 165.44)
	1		mRNA	3	19470	H-1	4.79 (1.21 to 8.36)
	2		mRNA	3	19752	·	32.68 (1.65 to 63.72)
						0	100
						e Insidence Data	
						Incidence Rate	

* The analysis includes collaborative analysis of data within a single study and across multiple studies

Image: Children and adolescents mRNA 2 4632
1 2* 4632 →→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→→
2 2* 4632 → 25.70 (6.68 to 98.1 1 Children and adolescents mRNA 2 4528 → 31.84 (0.00 to 244 1 Immunocompromised Viralvector 1* 104 → 55.37 (0.00 to 171 2 Children and adolescents mRNA 2 4528 → 31.96 (0.00 to 332 2 Immunocompromised Viralvector 1* 104 → 30.86 (0.00 to 131
1 Children and adolescents mRNA 2 4528 → 31.84 (0.00 to 244 1 Immunocompromised Viralvector 1* 104 → 55.37 (0.00 to 171 2 Children and adolescents mRNA 2 4528 → 31.96 (0.00 to 332 2 Immunocompromised Viralvector 1* 104 → 30.86 (0.00 to 131
1 Immunocompromised Viralvector 1* 104 ● > 55.37 (0.00 to 171 2 Children and adolescents mRNA 2 4528 ● > 31.96 (0.00 to 332 2 Immunocompromised Viralvector 1* 104 ● > 30.86 (0.00 to 131 2 Immunocompromised Viralvector 1* 104 ● > 30.86 (0.00 to 131
2 Children and adolescents mRNA 2 4528 → 31.96 (0.00 to 332 2 Immunocompromised Viralvector 1* 104 → 30.86 (0.00 to 131 2 Introduction 1* 104 → 30.86 (0.00 to 131
2 Immunocompromised Viralvector 1* 104 → 30.86 (0.00 to 131
Cohort
1 14 4772 <u>22.78 (12.48 to 41</u>
2 15* 5889 - 33.06 (22.23 to 49
1 Autoimmune 2* 2119 + 57.08 (0.00 to 117
2 Autoimmune 2* 2079 ← → 68.70 (0.00 to 198
1 Cancer 3 1248 14.35 (0.00 to 39.0
2 Cancer 4* 2748 29.13 (0.89 to 57.3
1 Immunocompromised 8 1310 - 30.66 (9.97 to 51.3
2 Immunocompromised 8 836 39.99 (17.88 to 62
1 mRNA 11 4056 32.72 (15.60 to 49
1 Viralvector 2 1382
2 mRNA 12 4789 43.32 (24.73 to 61
2 Viralvector 2 227 → 26.51 (0.00 to 328
Unspecified 3 6058 31.73 (1.44 to 699
Unspecified Autoimmune 2 1696 - 73.75 (0.00 to 821
Unspecified Cancer 1 762 H 14.62 (11.38 to 17
Unspecified mRNA 2 2283 - 16.19 (7.61 to 24.7
Loss-sectional
1 11* 28470 - 36.20 (18.27 to 71
2 10 [*] 27954 → 52.84 (22.68 to 12
1 Pregnant 2* 19416 44.84 (27.88 to 61
1 Autoimmune 4* 2418 18.29 (0.00 to 26.4
2 Pregnant 2* 19375 → 96.29 (50.61 to 14
2 Autoimmune 4* 1976 35.75 (0.00 to 73.6
2 Multiple sclerosis 1* 719 → 211.39 (0.00 to 60
1 mRNA 7* 25741 → 86.77 (0.00 to 233
1 Viralvector 2* 1165 - 20.40 (6.50 to 34.3
2 mRNA 8* 25982 + 120.63 (0.00 to 27
0 100

Figure 17. Fatigue Pooled Incidence Rate

* The analysis includes collaborative analysis of data within a single study and across multiple studies.

Study Design	Dose	Population type	Vaccine type	N.studies	N.individuals	IP (95% CI)
Trial						
	1			6*	5296	
	2			6*	5297	+ 47.20 (20.84 to 106.90)
	1	Childre and adolescents	mRNA	3	5134	 23.00 (3.24 to 163.09)
	1	Immunocompromsied	Viralvector	1*	54	● 56.55 (0.00 to 1000.00)
	1	Autoimmune	Inactivated	2*	104	← 49.37 (3.13 to 777.75)
	2	Childre and adolescents	mRNA	3	5134	→ 53.96 (4.68 to 621.56)
	2	Immunocompromsied	Viralvector	1*	54	→ 35.86 (0.00 to 1000.00)
	2	Autoimmune	Inactivated	2*	104	→ 36.89 (0.00 to 1000.00)
Cohort						
	1			36*	12882	39.04 (29.88 to 51.00)
	2			44*	13629	101.29 (74.77 to 137.23)
	Unspecified			13	10157	45.35 (22.03 to 93.35)
	1	Autoimmune		7*	5403	44.99 (23.36 to 86.63)
	1	Cancer		12*	5150	33.43 (22.09 to 50.61)
	1	Lactating		1*	96	→ 138.09 (46.65 to 408.74)
	1	Pregnant		2	114	13.25 (1.95 to 90.17)
	1	Immunocompromsied		10*	1239	37.05 (18.09 to 75.89)
	2	Autoimmune		8*	5772	117.23 (63.33 to 217.04)
	2	Cancer		14*	5261	→ 81.27 (50.22 to 131.52)
	2	Lactating		1*	96	645.60 (414.21 to 1000.00)
	2	Pregnant		2	114	→ 224.02 (1.70 to 1000.00)
	2	Immunocompromsied		14	1534	→ 59.55 (31.28 to 113.36)
	Unspecified	Autoimmune		2	4779	→ 86.68 (4.82 to 1000.00)
	Unspecified	Cancer		3	1082	14.33 (6.68 to 30.73)
	Unspecified	Pregnant		2	216	
	Unspecified	Immunocompromsied		6	4080	► 57.17 (11.59 to 282.06)
	1		mRNA	28*	10101	37.92 (27.39 to 52.50)
	1		Inactivated	2	1686	← ◆ 24.57 (4.15 to 145.35)
	2		mRNA	35*	10886	→ 117.38 (83.03 to 165.94)
	2		Inactivated	4	2082	◆ 43.41 (4.10 to 459.15)
	Unspecified		mRNA	10	6517	← ◆ 47.27 (18.87 to 118.37)
Cross -Sectiona	al					
	1			14*	24777	38.81 (23.63 to 63.73)
	2			13*	19216	→ 113.99 (71.06 to 182.83)
	Unspecified			9.	5930	→ 120.98 (67.98 to 215.32)
	1	Autoimmune		7.	5676	47.37 (24.18 to 92.81)
	1	Cancer		2*	820	→ 37.70 (11.74 to 121.04)
	1	Pregnant		2"	1/151	14.73 (4.72 to 45.99)
	2	Autoimmune		6-	5006	→ 122.76 (69.55 to 216.68)
	2	Cancer		2.	/14	→ 41.27 (3.78 to 451.09)
	2	Pregnant		2"	12394	→ 148.52 (56.86 to 387.91)
	Unspecified	Autoimmune		4"	6664	→ 136.67 (56.32 to 331.65)
	Unspecified	Multiple scierosis	-	2-	431	• 96.58 (20.62 to 452.40)
	1		MRNA	9.	19385	28.08 (14.84 to 53.14)
	1		Inactivated	2	430	7.51 (0.07 to 830.40)
	1		viralvector	31	996	► 63.71 (15.32 to 457.21)
	2		mRNA	10	14329	→ 128.00 (74.99 to 218.46)
	Unspecified		mRNA	2'	2371	199.88 (57.65 to 693.05)
	Unspecified		inactivated	2	701	24.60 (0.01 to 1000.00)
						0 100
						Incidence Rate

Figure 18. Fever Pooled Incidence Proportion

* The analysis includes collaborative analysis of data within a single study and across multiple studies.

IP: Incidence Proportion

Study Design	Dose	Population type	Vaccine type	N.studies	N.individuals		IR (95% CI)
Trial			a a berland on the bootst			l.	
	1			4	5188		→ 16.30 (2.21 to 120.14)
	1	Children and adolescents	mRNA	3	5134	•	17.18 (0.00 to 58.77)
	2			4	5188	•	→ 17.05 (2.77 to 104.89)
	2	Children and adolescents	mRNA	3	5134	•	→ 28.42 (0.00 to 106.87)
Cohort							
	1			9*	5088		15.70 (7.64 to 32.25)
	2			9*	4518		24.05 (11.19 to 51.68)
	1	Autoimmune		1*	3343	·	36.33 (0.00 to 74.54)
	1	Cancer		3	1248		5.72 (0.00 to 12.76)
	1	Immunocompromised		4	520	· · · · · · · · · · · · · · · · · · ·	32.48 (0.00 to 71.26)
	2	Autoimmune		1*	3080	•	→ 63.51 (0.00 to 210.87)
	2	Cancer		3	995	• • • •	25.90 (0.00 to 79.61)
	2	Immunocompromised		4	403		28.42 (1.30 to 55.55)
	1		mRNA		4477		23.86 (7.01 to 40.71)
	2		mRNA	7	4285	· · · · · · · · · · · · · · · · · · ·	33.48 (12.52 to 54.43)
Cross-section	al						,
	1			4*	10683	· · · · · · · · · · · · · · · · · · ·	24.64 (7.47 to 81.21)
	2			4*	7760		→ 80.35 (40.36 to 159.95)
	1	Autoimmune	Viralvector	1*	724		14.60 (0.00 to 36.13)
	2	Pregnant		2*	6759		→ 68.74 (9.25 to 128.24)
	1		mRNA	2*	9221		12.69 (0.00 to 33.49)
	2		mRNA	3	6787		- 66.75 (34.72 to 98.77)
						0	100
						• <u></u>	→ →
						Incidence Rate	

Figure 19. Myalgia Pooled Incidence Rate

* The analysis includes collaborative analysis of data within a single study and across multiple studies.

Figure 20. Gastrointestinal Symptoms Pooled Incidence Rate

Study Design	Dose	Population type	Vaccine type	N.studies	N.individuals		IR (95% CI)
Trial						1	
	1			4	5188	• • • • •	6.10 (6.10 to 41.19)
	2			4	5188		→ 6.53 (0.57 to 74.43)
	1	Children and adolescents	mRNA	3	5112	· · · · · · · · · · · · · · · · · · ·	7.93 (0.00 to 24.44)
	2	Children and adolescents	mRNA	3	5113	•	12.12 (0.00 to 48.26)
	Unspecified	Cancer	mRNA	1*	3813	1	0.62 (0.00 to 2.03)
Cohort							
	1			13*	5601	H	5.30 (3.00 to 9.35)
	2			9*	5589		7.36 (4.05 to 13.56)
	1	Autoimmune		2*	3406		10.71 (0.00 to 23.72)
	1	Cancer		4*	1292		3.69 (0.00 to 8.19)
	1	Immunocompromised		7	821	→ →→	6.45 (0.67 to 12.23)
	2	Autoimmune		1*	3080	+ +	
	2	Cancer		4*	2180)	3.17 (1.24 to 5.10)
	2	Immunocompromised		4*	329		9.21 (3.58 to 14.84)
	1		mRNA	10	4816	·	7.09 (3.09 to 11.10)
	1		Viralvector	2	244	•	
	2		mRNA	7*	5393		12.70 (5.22 to 20.17)
Cross-section	al			1979 B			
	1			7*	11143	· • · · · · · · · · · · · · · · · · · ·	7.60 (2.17 to 26.64)
	1	Autoimmune		2*	687		3.44 (0.00 to 8.63)
	1	Pregnant		2*	9221	+	7.29 (0.00 to 18.44)
	1		mRNA	6*	10185	•	→ 19.02 (0.00 to 56.01)
	1		Viralvector	1*	47	•	1.21 (0.00 to 14.60)
	2			7*	8534	•	→ 12.37 (2.74 to 55.89)
	2		mRNA	6*	7727	1	→ 45.92 (0.00 to 123.61)
	2	Autoimmune		2*	684		4.58 (0.00 to 14.57)
	2	Pregnant		2*	6759	•	29.58 (0.00 to 76.37)
						0	50
						Incidence Rate	→

* The analysis includes collaborative analysis of data within a single study and across multiple studies.

Study Design	Dose	Population type	Vaccine type	N.studies	N.individuals		IP (95% CI)
Trial						1	
	1	Autoimmune	Inactivated	2*	104	• • • • • • • • • • • • • • • • • • •	61.61 (24.82 to 152.94)
	2	Autoimmune	Inactivated	2*	104	► →	80.15 (15.98 to 401.83)
Cohort							
	1			4*	1747	·•	24.38 (6.38 to 93.12)
	2			5*	1795	·•	31.17 (11.89 to 81.72)
	1	Autoimmune		3*	1686	⊢ ● →	24.52 (4.62 to 130.03)
	1	Immunocompromised		1	61	• • • • • • • • • • • • • • • • • • • •	16.39 (0.41 to 87.98)
	2	Autoimmune		3*	1686	· · · · · · · · · · · · · · · · · · ·	28.39 (5.83 to 138.17)
	2	Immunocompromised		2*	109	• • • • • • • • • • • • • • • • • • •	40.08 (12.33 to 130.27)
	1		mRNA	3*	837	·	131.15 (24.77 to 694.66)
	1		Inactivated	1	910	·	82.41 (65.37 to 102.21)
	2		mRNA	4*	854	⊢ ●−−−−−−	20.07 (5.07 to 79.49)
	2		Inactivated	2*	941	·	88.90 (58.76 to 134.49)
Cross-sectiona	al						
	1	Autoimmune		1*	441	— — — →	17.02 (1.03 to 280.22)
	1	Autoimmune	Viralvector	1	47		42.19 (0.00 to 1000.00)
	1	Autoimmune	mRNA	1	394	—	7.94 (0.00 to 1000.00)
	2	Autoimmune		1*	438	•	8.23 (0.95 to 70.59)
	2	Autoimmune	Viralvector	1	44		0.00 (0.00 to 80.41)
	2	Autoimmune	mRNA	1*	394	,	9.20 (0.00 to 1000.00)
						0 10	00
						()	,
						Incidence Rate	

Figure 21. Ear, Nose, Throat symptoms Pooled Incidence Proportion

* The analysis includes collaborative analysis of data within a single study and across multiple studies.

IP: Incidence Proportion

Figure 22. Conjunctivitis and Uveitis Pooled Incidence Proportion

Study Design	Dose	Population type	Vaccine type	N.studies	N.individuals		IP (95% CI)
Trial							
	1	Autoimmune	Inactivated	2	363		19.23 (18.96 to 19.49)
	2	Autoimmune	Inactivated	2	363	н	5.77 (5.30 to 6.23)
Cohort							
	1	Autoimmune	mRNA	1	807	•	1.45 (0.03 to 8.09)
	2	Autoimmune	mRNA	1	807	+ • +	2.91 (0.35 to 10.49)
Case-Control							
	1	Autoimmune		1*	942		- 21.14 (9.16 to 48.77)
	2	Autoimmune		1*	942		→ 28.48 (0.61 to 1000.00)
						0	50 →
						Incidence Rate	

* The analysis includes collaborative analysis of data within a single study and across multiple studies.

IP: Incidence Proportion